Literature DB >> 25492569

Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine.

Arne Reimers1,2, Wenche Sjursen3,4, Grethe Helde5, Eylert Brodtkorb5,6.   

Abstract

The gene encoding uridine diphosphate glucuronosyltransferase (UGT) 1A4 shows considerable polymorphism. Several common drugs are metabolised by UGT1A4, among them lamotrigine (LTG). Experimental and clinical studies suggest that certain variants of UGT1A4 are associated with altered enzyme activity. However, results are conflicting. This clinical study aimed to investigate the frequencies of two common UGT1A4 variants, *2 (P24T) and *3 (L48V), and their potential effects on serum concentrations of LTG. The *2 variant was associated with a trend towards higher serum concentrations, while the *3 variant was associated with significantly lower serum concentrations of LTG. The calculated allele frequencies were in the same range as in earlier studies on Caucasian populations. To our knowledge, this is the first study suggesting a clinical effect of UGT1A4*2. Further study is needed to confirm this finding.

Entities:  

Keywords:  Glucuronidation; Lamotrigine; Polymorphisms; Serum concentration; UGT1A4

Mesh:

Substances:

Year:  2014        PMID: 25492569     DOI: 10.1007/s13318-014-0247-0

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  39 in total

1.  Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data.

Authors:  Z Hussein; J Posner
Journal:  Br J Clin Pharmacol       Date:  1997-05       Impact factor: 4.335

Review 2.  Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?

Authors:  Svein I Johannessen; Torbjörn Tomson
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Drug glucuronidation in clinical psychopharmacology.

Authors:  H L Liston; J S Markowitz; C L DeVane
Journal:  J Clin Psychopharmacol       Date:  2001-10       Impact factor: 3.153

4.  Functional analysis of UGT1A4(P24T) and UGT1A4(L48V) variant enzymes.

Authors:  Jin Zhou; Upendra A Argikar; Rory P Remmel
Journal:  Pharmacogenomics       Date:  2011-11-02       Impact factor: 2.533

Review 5.  Enzyme induction with antiepileptic drugs: cause for concern?

Authors:  Martin J Brodie; Scott Mintzer; Alison M Pack; Barry E Gidal; Charles J Vecht; Dieter Schmidt
Journal:  Epilepsia       Date:  2012-09-27       Impact factor: 5.864

Review 6.  Human placenta: a human organ for developmental toxicology research and biomonitoring.

Authors:  P Myllynen; M Pasanen; O Pelkonen
Journal:  Placenta       Date:  2005-05       Impact factor: 3.481

7.  UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation.

Authors:  Asami Mori; Yoshihiro Maruo; Masaru Iwai; Hiroshi Sato; Yoshihiro Takeuchi
Journal:  Drug Metab Dispos       Date:  2005-02-11       Impact factor: 3.922

8.  Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy.

Authors:  Inger Ohman; Olof Beck; Sigurd Vitols; Torbjörn Tomson
Journal:  Epilepsia       Date:  2007-12-11       Impact factor: 5.864

9.  Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.

Authors:  Keith L Davis; Sean D Candrilli; Heather M Edin
Journal:  Epilepsia       Date:  2007-11-21       Impact factor: 5.864

10.  Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants.

Authors:  Dongxiao Sun; Gang Chen; Ryan W Dellinger; Kimberly Duncan; Jia-Long Fang; Philip Lazarus
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

View more
  13 in total

1.  Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy.

Authors:  Iva Klarica Domjanović; Mila Lovrić; Vladimir Trkulja; Željka Petelin-Gadže; Lana Ganoci; Ivana Čajić; Nada Božina
Journal:  Br J Clin Pharmacol       Date:  2018-07-08       Impact factor: 4.335

2.  Authors' Reply to Standing et al.: "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials".

Authors:  Sven C van Dijkman; Nico C B de Jager; Willem M Rauwé; Meindert Danhof; Oscar Della Pasqua
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

3.  Lack of Association of Generic Brittle Status with Genetics and Physiologic Measures in Patients with Epilepsy.

Authors:  Sharmila Das; Dong Guo; Xiaohui Jiang; Wenlei Jiang; Yan Shu; Tricia Y Ting; James E Polli
Journal:  Pharm Res       Date:  2020-02-26       Impact factor: 4.200

4.  Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.

Authors:  Jiachang Gong; Lisa Iacono; Ramaswamy A Iyer; William G Humphreys; Ming Zheng
Journal:  Br J Clin Pharmacol       Date:  2018-04-10       Impact factor: 4.335

5.  Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.

Authors:  Yao Lu; Youxin Fang; Xunyi Wu; Chunlai Ma; Yue Wang; Lan Xu
Journal:  Eur J Clin Pharmacol       Date:  2016-11-29       Impact factor: 2.953

6.  Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy.

Authors:  Kazuyuki Inoue; Yoshiaki Yamamoto; Eri Suzuki; Toshiki Takahashi; Akiko Umemura; Yukitoshi Takahashi; Katsumi Imai; Yushi Inoue; Keita Hirai; Daiki Tsuji; Kunihiko Itoh
Journal:  Eur J Clin Pharmacol       Date:  2016-01-20       Impact factor: 2.953

Review 7.  The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling.

Authors:  Justine Badée; Stephen Fowler; Saskia N de Wildt; Abby C Collier; Stephan Schmidt; Neil Parrott
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

Review 8.  Precision medicine in women with epilepsy: The challenge, systematic review, and future direction.

Authors:  Yi Li; Sai Zhang; Michael P Snyder; Kimford J Meador
Journal:  Epilepsy Behav       Date:  2021-03-25       Impact factor: 2.937

9.  Transcriptional Regulation of Drug Metabolizing CYP Enzymes by Proinflammatory Wnt5A Signaling in Human Coronary Artery Endothelial Cells.

Authors:  Tom Skaria; Esther Bachli; Gabriele Schoedon
Journal:  Front Pharmacol       Date:  2021-05-17       Impact factor: 5.810

10.  Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors.

Authors:  E E J Kasteel; K Darney; N I Kramer; J L C M Dorne; L S Lautz
Journal:  Arch Toxicol       Date:  2020-05-15       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.